Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

Abstract Aims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline clinical profile and prognostic role of finerenone in patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Gonzalo Luis Alonso Salinas, Amaia Martínez León, Diego Aguiar Cano, Alberto Esteban‐Fernández, José María Viéitez Flórez, Susana delPrado Díaz, Juan Górriz‐Magaña, Gregorio deLara Delgado, Rafael González‐Manzanares, Pedro Caravaca‐Pérez, Francisco J. Pastor‐Pérez, Sandra Valdivieso‐Moré, Juan Quiles, Inés Ponz, Vanessa Escolar, Edison Omar Boada Lincango, Néstor Báez‐Ferrer, Gonzalo Gallego, Luis Almenar, Luis Gutiérrez de la Varga, Pau Codina, Alejandro Recio Mayoral, Aleix Fort, María Jesús Pinilla Lozano, David González‐Calle, Inés Gómez‐Otero, Cristina Salazar Mosteiro, Marta Cobo, Jesús Piqueras‐Flores, Clara Bonanad, Ana Huerta, Maria Ferré Vallverdú, Pablo Díez‐Villanueva
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:ESC Heart Failure
Subjects:
Heart failure
Finerenone
Real‐world evidence
Ejection fraction spectrum
Clinical outcomes
Online Access:https://doi.org/10.1002/ehf2.15260
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline clinical profile and prognostic role of finerenone in patients with HF, irrespective of ejection fraction. Methods and results The study is a multicentre, observational registry, including regional and tertiary hospitals. The registry incorporates contributions from cardiology, internal medicine, and nephrology departments, ensuring comprehensive data collection. Patients with previous history of decompensated HF and elevated natriuretic peptides (NPs) will be included and classified into two groups: Those initiating finerenone will constitute the study cohort, with a 1:1 matched control cohort including those patients not receiving finerenone. Follow‐up will occur at 6 and 12 months (and optional 3 and 5 years). Endpoints will include the incidence of HF exacerbations requiring intravenous therapy, hospitalizations, renal replacement therapy, and mortality due to cardiovascular or renal causes. Conclusions This study will provide valuable real‐world evidence on the clinical effectiveness and safety of finerenone across a wide range of HF patients, including those with reduced, mildly reduced, and preserved ejection fraction. By leveraging a large, representative, and controlled cohort, the findings aim to enhance clinical decision‐making and optimize the use of finerenone in routine practice, particularly in high‐risk patients with complex co‐morbidities.
ISSN:2055-5822

Similar Items